Showing 2871-2880 of 5909 results for "".
- Market Scope: Ophthalmic Deals Surge in 2018-2019; Most Transactions Involve New Ventureshttps://modernod.com/news/market-scope-ophthalmic-deals-surge-in-2018-2019-most-transactions-involve-new-ventures/2477195/Ophthalmic deals garnered over $9 billion from January 2018 through October 2019, driven largely by dry eye and retina related fundraising. Over 100 transactions occurred during this period, and over 80 percent of transaction are categorized as new ventures. The Novartis acquisition of Xii
- Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-cohesive-ophthalmic-viscosurgical-device-ovd/2477174/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new cohesive ophthalmic viscosurgical device (OVD) intended to provide surgeons with a new option in the continuum of cohesive and dispersive viscoelastics. “This is the second new OVD th
- NIH Launches First U.S. Clinical Trial of Patient-Derived Stem Cell Therapy to Replace Dying Cells in Retinahttps://modernod.com/news/nih-launches-first-u-s-clinical-trial-of-patient-derived-stem-cell-therapy-to-replace-dying-cells-in-retina/2477175/Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD). Geographic atrophy currently has no treatment.
- Eyesight Philanthropist James Chen Awarded Honorary Degree by University of Bathhttps://modernod.com/news/eyesight-philanthropist-james-chen-awarded-honorary-degree-by-university-of-bath/2477169/James Chen, a philanthropist committed to solving global problems associated with vision and eye care, has been awarded an honorary degree from the University of Bath, UK. He received his honorary LLD (Doctor of Laws) degree at the Assembly Rooms, Bath, on Tuesday 10 December (12:15 pm). I
- Joel Leftwich Named Executive Director of William L. Hudson BVI Workforce Innovation Centerhttps://modernod.com/news/joel-leftwich-named-executive-director-of-william-l-hudson-bvi-workforce-innovation-orkforce-innovation-center/2477155/Envision announced today that Joel Leftwich has been named executive director of the William L. Hudson BVI Workforce Innovation Center. The mission of the center, which is based out of Envision’s Wichita, Kansas headquarters, is to train and employ individuals with visual impairments, place them
- Leiters and Prodigy Health Enter into National Sales and Marketing Agreementhttps://modernod.com/news/leiters-and-prodigy-health-enter-into-national-sales-and-marketing-agreement/2477157/Leiters and Prodigy Health have entered into a national sales and marketing agreement that will permit Prodigy Health to bring its ProdigyVision technology platform to the Leiters portfolio of 503B compounded sterile preparations in collaboration with the Leiters sal
- Limelight Bio Emerges with $75 Million to Develop Next Generation Gene Therapieshttps://modernod.com/news/limelight-bio-emerges-with-75-million-to-develop-next-generation-gene-therapies/2477141/Limelight Bio, a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75 million in new financing funded by Apple Tree Partners (ATP), a life sciences innovation fund. Founded in 2017, Limelight Bio has developed proprietary technologies
- RightEye Vision System Receives Breakthrough Device Designation from the FDA for Parkinson’s Disease Testhttps://modernod.com/news/righteye-vision-system-receives-breakthrough-device-designation-from-the-fda-for-parkinsons-disease-test/2477133/RightEye announced that the RightEye Vision System has received breakthrough device designation from the FDA for a Parkinson’s Disease Test. The designation is designed to streamline the market clearance
- ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477112/ProQR Therapeutics announced that it received orphan drug designation (ODD) from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H m
- Lightmed Introduces New Design of LIGHTLas TruScan Pro Photocoagulatorhttps://modernod.com/news/lightmed-introduces-new-design-of-lightlas-truscan-pro-photocoagulator/2477108/Lightmed announced the launch of LIGHTLas TruScan Pro V2.0, the advanced and flexible pattern-scanning laser that’s configurable with up to four different wavelengths. The upgraded LIGHTLas TruScan Pro V2.0 features a slit lamp and integrated delivery system design, and a new ergonomic single col